These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22431574)

  • 21. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
    Cortes JE; Baccarani M; Guilhot F; Druker BJ; Branford S; Kim DW; Pane F; Pasquini R; Goldberg SL; Kalaycio M; Moiraghi B; Rowe JM; Tothova E; De Souza C; Rudoltz M; Yu R; Krahnke T; Kantarjian HM; Radich JP; Hughes TP
    J Clin Oncol; 2010 Jan; 28(3):424-30. PubMed ID: 20008622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Marin D; Ibrahim AR; Lucas C; Gerrard G; Wang L; Szydlo RM; Clark RE; Apperley JF; Milojkovic D; Bua M; Pavlu J; Paliompeis C; Reid A; Rezvani K; Goldman JM; Foroni L
    J Clin Oncol; 2012 Jan; 30(3):232-8. PubMed ID: 22067393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
    Hoyle M; Rogers G; Moxham T; Liu Z; Stein K
    Value Health; 2011 Dec; 14(8):1057-67. PubMed ID: 22152175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
    Santos FP; Alvarado Y; Kantarjian H; Verma D; O'Brien S; Mattiuzzi G; Ravandi F; Borthakur G; Cortes J
    Cancer; 2011 Mar; 117(5):982-91. PubMed ID: 20960502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
    Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
    Haematologica; 2010 Aug; 95(8):1415-9. PubMed ID: 20305139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Jabbour E; Kantarjian H; O'Brien S; Shan J; Quintas-Cardama A; Faderl S; Garcia-Manero G; Ravandi F; Rios MB; Cortes J
    Blood; 2011 Oct; 118(17):4541-6; quiz 4759. PubMed ID: 21803854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
    Sasaki K; Kantarjian H; Jabbour E; Ravandi F; Takahashi K; Konopleva M; Borthakur G; Garcia-Manero G; Wierda W; Daver N; Jain P; Satta T; Pierce S; Rios MB; Cortes JE
    Haematologica; 2016 Aug; 101(8):e324-7. PubMed ID: 27175025
    [No Abstract]   [Full Text] [Related]  

  • 28. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
    Shah NP; Kantarjian HM; Kim DW; Réa D; Dorlhiac-Llacer PE; Milone JH; Vela-Ojeda J; Silver RT; Khoury HJ; Charbonnier A; Khoroshko N; Paquette RL; Deininger M; Collins RH; Otero I; Hughes T; Bleickardt E; Strauss L; Francis S; Hochhaus A
    J Clin Oncol; 2008 Jul; 26(19):3204-12. PubMed ID: 18541900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
    Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Leuk Lymphoma; 2018 May; 59(5):1105-1112. PubMed ID: 28838287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
    Roy L; Tomowiak C; Guilhot F
    Blood; 2011 Nov; 118(19):5096-8. PubMed ID: 21876122
    [No Abstract]   [Full Text] [Related]  

  • 32. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
    Hoffmann VS; Baccarani M; Lindoerfer D; Castagnetti F; Turkina A; Zaritsky A; Hellmann A; Prejzner W; Steegmann JL; Mayer J; Indrak K; Colita A; Rosti G; Pfirrmann M
    Leukemia; 2013 Oct; 27(10):2016-22. PubMed ID: 23752173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
    García-Gutiérrez V; Martinez-Trillos A; Lopez Lorenzo JL; Bautista G; Martin Mateos ML; Alvarez-Larrán A; Iglesias Pérez A; Romo Collado A; Fernandez A; Portero A; Cuevas B; Ruiz C; Romero E; Ortega F; Mata I; Tallón J; García Garay Mdel C; Ramirez Sánchez MJ; de Las Heras N; Giraldo P; Bobillo S; Guinea JM; Deben G; Valencia S; Sebrango A; Boqué C; Maestro B; Steegmann JL
    Am J Hematol; 2015 May; 90(5):429-33. PubMed ID: 25683327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
    Jain P; Kantarjian H; Nazha A; O'Brien S; Jabbour E; Romo CG; Pierce S; Cardenas-Turanzas M; Verstovsek S; Borthakur G; Ravandi F; Quintás-Cardama A; Cortes J
    Blood; 2013 Jun; 121(24):4867-74. PubMed ID: 23620574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.
    Breccia M; Latagliata R; Molica M; Colafigli G; Mancini M; Diverio D; Tafuri A; Alimena G
    Am J Hematol; 2015 May; 90(5):E95-6. PubMed ID: 25683237
    [No Abstract]   [Full Text] [Related]  

  • 36. Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
    Molica M; Colafigli G; Scalzulli E; Alunni Fegatelli D; Chiatamone Ranieri S; Rizzo L; Diverio D; Efficace F; Latagliata R; Foà R; Breccia M
    Ann Hematol; 2019 Aug; 98(8):1891-1904. PubMed ID: 31079264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia.
    Takami A; Ohtake S; Morishita E; Terasaki Y; Fukushima T; Kurokawa T; Sugimori N; Matano S; Ohata K; Saito C; Yamaguchi M; Hosokawa K; Yamazaki H; Kondo Y; Nakao S
    Int J Hematol; 2012 Sep; 96(3):357-63. PubMed ID: 22893108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
    Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
    Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
    Cortes JE; Kantarjian HM; Goldberg SL; Powell BL; Giles FJ; Wetzler M; Akard L; Burke JM; Kerr R; Saleh M; Salvado A; McDougall K; Albitar M; Radich J;
    J Clin Oncol; 2009 Oct; 27(28):4754-9. PubMed ID: 19720924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.